Biomedical subjects

Darja Kanduc

Publications and source records attributed to Darja Kanduc.

22 records · Page 2Linked to original sources

PubMed2002

Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)-globin and human cytokeratin 7.

The possible biochemical factors able to affect the in vitro expression of the high-risk human papillomavirus type 16 (HPV16) E7 oncoprotein have been analyzed. Evidence is provided that E7 mRNA stability is increased and, conversely, transcript translation is inhibited by binding to a 32-kDa protein from rabbit reticulocyte lysate; sequence analysis identified the 32-kDa binding protein as rabbit alpha(1)-globin protein; and interaction between rabbit alpha(1)-globin and E7 mRNA occurs through the 6-mer peptide SEQIKA present in human cytokeratin 7 protein. The in vitro data were confirmed by the occurrence of HPV16 E7 mRNA-cytokeratin 7 binding in squamous cervical cancer SiHa cells.

Amino Acid Sequence↗

PubMed2002

Cell death: apoptosis versus necrosis (review).

Cell death and the subsequent post-mortem changes, called necrosis, are integral parts of normal development and maturation cycle. Despite the importance of this process, the mechanisms underlying cell death are still poorly understood. In the recent literature, cell death is said to occur by two alternative, opposite modes: apoptosis, a programmed, managed form of cell death, and necrosis, an unordered and accidental form of cellular dying. The incorrect consequence is the overlapping of: a) the process whereby cells die, cell death; and b) the changes that the cells and tissues undergo after the cells die. Only the latter process can be referred to as necrosis and represents a process in cell life. In this review, we discuss the excellent basic research developed in this field during last decades and problems that remain to be resolved in defining both experimentally and mechanicistically the events that lead to and characterize cell death.

Animals↗

PubMedDate not supplied

Cancer prevention and therapy: strategies and problems.

During the next years, molecular diagnostic science and the pharmaceutical industry will face increasing demand for personalized medicine. Therapeutic treatments should be tailored to the needs of individual patient. Patients will inquire for information about potential tumor detection at an early stage when disease can be more likely to be arrested or cured with specific regimens of drug therapy. To respond to this demand, science and industry need to modulate therapeutic approaches to the continuous development of cancer. Now more than ever, it is necessary to fill the knowledge hiatus between the "beginning" and the "end" of cancer development, i.e we need to critically analyze the extensive multi-step process of cancer development that still remains poorly understood.

Humans↗

PubMedDate not supplied

Clinical applications of DNA microarray analysis.

Microarray technology provides a revolutionary macro-genetic and bioinformatic-rich platform for understanding human diseases. DNA microarrays facilitate the study of complex diseases, enabling several observations simultaneously that can become foundations for newer hypotheses-shifting us towards a non-reductionist approach to biological phenomenon. This appears of particular value for scientific and clinical dissection of tumor pathologies. Despite the tremendous potential presented by microarray technology for the investigation of disease, concrete insights and advances that translate to the clinical setting are only recently beginning to be tapped. Here, we discuss specific examples of how microarray technology is being integrated into our ever-evolving approach to clinical disease. We focus on molecular strategies for (a) disease classification, (b) disease outcome, and (c) disease mechanisms.

Gene Expression Profiling↗